Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Neisseria meningitidis causes endemic meningococcal disease worldwide. Serogroups B and C are responsible for the majority of cases of meningococcal disease in Europe, serogroups B, C and Y cause most disease in the Americas, and serogroups A, C and W135 predominate in Asia and Africa. Polysaccharide vaccines against meningococcal serogroups A, C, Y and W135 have been available for several decades, but have been little used due to poor immunogenicity in young children and minimal effects on nasopharyngeal carriage. Conversely, the introduction of the conjugate serogroup C meningococcal vaccine has dramatically changed the epidemiology of the disease in industrialized nations, showing potential for broader control with A, C, Y and W135 conjugates, and leaving serogroup B as the predominant cause of disease. Development of vaccines for prevention of serogroup B disease in industrialized nations and serogroup A conjugate vaccines for Africa could lead to global control of meningococcal disease.

Original publication

DOI

10.1586/erv.10.3

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

03/2010

Volume

9

Pages

285 - 298

Keywords

Africa, Americas, Asia, Endemic Diseases, Europe, Humans, Meningitis, Meningococcal, Meningococcal Vaccines, Neisseria meningitidis